Cargando…

Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy

Natural Killer T (NKT) cells are unique lymphocytes characterized by their expression of a single invariant antigen receptor encoded by Vα14Jα18 in mice and Vα24Jα18 in humans, which recognizes glycolipid antigens in association with the monomorphic CD1d molecule. NKT cells mediate adjuvant activity...

Descripción completa

Detalles Bibliográficos
Autores principales: TANIGUCHI, Masaru, HARADA, Michishige, DASHTSOODOL, Nyambayar, KOJO, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Academy 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631895/
https://www.ncbi.nlm.nih.gov/pubmed/26194854
http://dx.doi.org/10.2183/pjab.91.292
_version_ 1782398922710319104
author TANIGUCHI, Masaru
HARADA, Michishige
DASHTSOODOL, Nyambayar
KOJO, Satoshi
author_facet TANIGUCHI, Masaru
HARADA, Michishige
DASHTSOODOL, Nyambayar
KOJO, Satoshi
author_sort TANIGUCHI, Masaru
collection PubMed
description Natural Killer T (NKT) cells are unique lymphocytes characterized by their expression of a single invariant antigen receptor encoded by Vα14Jα18 in mice and Vα24Jα18 in humans, which recognizes glycolipid antigens in association with the monomorphic CD1d molecule. NKT cells mediate adjuvant activity to activate both CD8T cells to kill MHC-positive tumor cells and NK cells to eliminate MHC-negative tumor at the same time in patients, resulting in the complete eradication of tumors without relapse. Therefore, the NKT cell-targeted therapy can be applied to any type of tumor and also to anyone individual, regardless of HLA type. Phase IIa clinical trials on advanced lung cancers and head and neck tumors have been completed and showed significantly prolonged median survival times with only the primary treatment. Another potential treatment option for the future is to use induced pluripotent stem cell (iPS)-derived NKT cells, which induced adjuvant effects on anti-tumor responses, inhibiting in vivo tumor growth in a mouse model.
format Online
Article
Text
id pubmed-4631895
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Japan Academy
record_format MEDLINE/PubMed
spelling pubmed-46318952016-03-03 Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy TANIGUCHI, Masaru HARADA, Michishige DASHTSOODOL, Nyambayar KOJO, Satoshi Proc Jpn Acad Ser B Phys Biol Sci Review Natural Killer T (NKT) cells are unique lymphocytes characterized by their expression of a single invariant antigen receptor encoded by Vα14Jα18 in mice and Vα24Jα18 in humans, which recognizes glycolipid antigens in association with the monomorphic CD1d molecule. NKT cells mediate adjuvant activity to activate both CD8T cells to kill MHC-positive tumor cells and NK cells to eliminate MHC-negative tumor at the same time in patients, resulting in the complete eradication of tumors without relapse. Therefore, the NKT cell-targeted therapy can be applied to any type of tumor and also to anyone individual, regardless of HLA type. Phase IIa clinical trials on advanced lung cancers and head and neck tumors have been completed and showed significantly prolonged median survival times with only the primary treatment. Another potential treatment option for the future is to use induced pluripotent stem cell (iPS)-derived NKT cells, which induced adjuvant effects on anti-tumor responses, inhibiting in vivo tumor growth in a mouse model. The Japan Academy 2015-07-21 /pmc/articles/PMC4631895/ /pubmed/26194854 http://dx.doi.org/10.2183/pjab.91.292 Text en © 2015 The Japan Academy This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
TANIGUCHI, Masaru
HARADA, Michishige
DASHTSOODOL, Nyambayar
KOJO, Satoshi
Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
title Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
title_full Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
title_fullStr Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
title_full_unstemmed Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
title_short Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
title_sort discovery of nkt cells and development of nkt cell-targeted anti-tumor immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631895/
https://www.ncbi.nlm.nih.gov/pubmed/26194854
http://dx.doi.org/10.2183/pjab.91.292
work_keys_str_mv AT taniguchimasaru discoveryofnktcellsanddevelopmentofnktcelltargetedantitumorimmunotherapy
AT haradamichishige discoveryofnktcellsanddevelopmentofnktcelltargetedantitumorimmunotherapy
AT dashtsoodolnyambayar discoveryofnktcellsanddevelopmentofnktcelltargetedantitumorimmunotherapy
AT kojosatoshi discoveryofnktcellsanddevelopmentofnktcelltargetedantitumorimmunotherapy